Akums Drugs Faces IT Probe Amidst Weak Standalone Earnings

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSatyam Jha|Published at:
Akums Drugs Faces IT Probe Amidst Weak Standalone Earnings
Overview

Akums Drugs reported Q3 FY26 results with consolidated revenue up 14.76% YoY, but standalone PAT plunged 31.71%. The company is under an ongoing Income Tax search operation, with its impact currently unascertainable, posing significant investor risk.

📉 The Financial Deep Dive

Akums Drugs and Pharmaceuticals Ltd. announced its un-audited financial results for the quarter and nine months ended December 31, 2025, presenting a mixed financial picture.

  • The Numbers:

    • Standalone Q3 FY26: Revenue from operations grew 9.24% YoY to ₹368.61 Cr, but Profit After Tax (PAT) saw a sharp 31.71% decline YoY to ₹28.11 Cr. Total expenses rose 17.03% YoY, outpacing revenue growth. Basic & Diluted EPS stood at ₹1.84 (vs ₹2.69 YoY).
    • Consolidated Q3 FY26: Revenue increased 14.76% YoY to ₹1159.59 Cr. Profit Before Tax rose 9.35% YoY to ₹99.57 Cr, significantly aided by a 135.75% surge YoY in 'Other Income' to ₹34.33 Cr. Consolidated PAT grew a modest 2.05% YoY to ₹67.67 Cr, with EPS at ₹4.33 (vs ₹4.26 YoY).
    • Nine Months FY26: Standalone PAT declined 27.71% YoY to ₹96.44 Cr, while Consolidated PAT fell 9.85% YoY to ₹175.06 Cr.

  • The Quality: Standalone profitability suffered due to escalating expenses. Consolidated performance was bolstered by substantial non-operational income, though overall nine-month PAT shows a declining trend.

  • The Grill: The most significant concern is the ongoing Income Tax search and seizure operation initiated in January 2025. Notices have been received for a block period (April 2018 - March 2025). The company explicitly states that the "potential impact of these proceedings on the financial results is currently unascertainable." This creates substantial uncertainty regarding future liabilities and governance. An exceptional item related to the implementation of new Labour Codes impacted profitability by ₹3.81 Cr standalone and ₹1.83 Cr consolidated. A notional interest expense of ₹19.71 Cr was recognized on a customer advance until 2032, leading to a deferred tax asset.

🚩 Risks & Outlook

  • Specific Risks: The primary risk is the Income Tax investigation, which could lead to significant financial penalties. The persistent decline in standalone PAT and margin compression are also key concerns.
  • The Forward View: Investors will be closely watching for any developments regarding the Income Tax probe. The successful integration and performance of the newly established wholly-owned subsidiary, Akums Healthcare Malta Private Limited, aimed at European expansion, will also be a point of observation.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.